Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.
0/5 보강
APA
Valenza C, Partridge AH, Regan MM (2026). Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.. Breast (Edinburgh, Scotland), 85, 104696. https://doi.org/10.1016/j.breast.2026.104696
MLA
Valenza C, et al.. "Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.." Breast (Edinburgh, Scotland), vol. 85, 2026, pp. 104696.
PMID
41547594 ↗
같은 제1저자의 인용 많은 논문 (4)
- Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
- Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study.
- Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
- Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?
📖 전문 본문 읽기 PMC JATS · ~13 KB · 영문
CRediT authorship contribution statement
CRediT authorship contribution statement
Carmine Valenza: Conceptualization, Writing – original draft. Ann H. Partridge: Conceptualization, Writing – review & editing. Meredith M. Regan: Conceptualization, Writing – review & editing.
Carmine Valenza: Conceptualization, Writing – original draft. Ann H. Partridge: Conceptualization, Writing – review & editing. Meredith M. Regan: Conceptualization, Writing – review & editing.
Funds
Funds
None.
None.
Declaration of competing interest
Declaration of competing interest
MMR reports research grants to institution from ETOP IBCSG Partners Foundation (including Biotheranostics, Novartis, Pfizer, and Roche) and Bristol-Myers Squibb; consulting fees from Bristol-Myers Squibb, TerSera, and Tolmar; honoraria from Bristol-Myers Squibb, McGill University funded by Merck, and St. Gallen Oncology Conferences; participating on the data safety monitoring board of Austrian BCSG and on an advisory board of AstraZeneca, TerSera, and Tolmar.
AP reported Wolters Kluwer-royalties for authorship of UpToDate.
All the competing interests were outside the submitted work. All other authors have no potential conflicts of interest to disclose.
MMR reports research grants to institution from ETOP IBCSG Partners Foundation (including Biotheranostics, Novartis, Pfizer, and Roche) and Bristol-Myers Squibb; consulting fees from Bristol-Myers Squibb, TerSera, and Tolmar; honoraria from Bristol-Myers Squibb, McGill University funded by Merck, and St. Gallen Oncology Conferences; participating on the data safety monitoring board of Austrian BCSG and on an advisory board of AstraZeneca, TerSera, and Tolmar.
AP reported Wolters Kluwer-royalties for authorship of UpToDate.
All the competing interests were outside the submitted work. All other authors have no potential conflicts of interest to disclose.
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.